Researchers compared ribociclib 400 mg with ribociclib 600 mg plus a nonsteroidal aromatase inhibitor in patients with ...
Researchers examined invasive disease-free survival rates at 4 years in a randomized phase 3 trial of adjuvant treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback